CXCR4 and cancer: We expected this regime to maintain sufficiently low the fraction of CXCR4+ cancer cells remaining in primary tumors and metastatic foci, along the treatment period, as to efficiently block metastasis and/or foci growth, provided that CXCR4+ cancer cells act as MetSCs.